Vector-borne disease
MONDO:0100120An infectious disease where a pathogen is carried and transmitted by another organism that acts as disease vector.
Also known as: vector-borne infection, vector-borne infectious disease
408 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New west nile vaccine enters first human tests
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 28, 2026 00:00 UTC
-
New malaria vaccine shows promise in early human trial
⭐️ VACCINE ⭐️ OngoingThis early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 28, 2026 00:00 UTC
-
New yellow fever vaccine shows promise in Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThis Phase 2 study tests a new yellow fever vaccine (vYF) against the current licensed vaccine (Stamaril) in 690 healthy adults aged 18-60 in Europe and Asia. Participants receive one shot, and researchers measure immune response and safety over 5 years. The goal is to see if the…
Phase: PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:01 UTC
-
New vaccine could stop deadly lassa fever
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new vaccine called LASSARAB, designed to protect against Lassa fever, a serious viral illness. The vaccine uses a modified rabies virus to deliver the Lassa antigen and includes an adjuvant to boost the immune response. 55 healthy adults will r…
Phase: PHASE1 • Sponsor: Wilbur Chen, MD, MS • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
Promising lyme vaccine moves to final testing phase
⭐️ VACCINE ⭐️ OngoingThis study tests a new Lyme disease vaccine (VLA15) in about 200 healthy adults aged 18 to 44. Participants receive five shots over two years—four of the vaccine and one of salt water—to see if different timing schedules are safe and produce a strong immune response. The goal is …
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New malaria vaccine dosing strategy tested in Early-Stage trial
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests whether giving the R21/Matrix-M malaria vaccine in a new, escalating-dose schedule is safe and creates a strong immune response. It involves 36 healthy adults in the UK who have never had malaria. The goal is to find a better way to protect people fro…
Phase: PHASE1 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
Promising malaria vaccine candidates enter key trial in african children
⭐️ VACCINE ⭐️ OngoingThis study tests two experimental malaria vaccines in 360 children aged 5 to 36 months in Burkina Faso, a country where malaria is common. The vaccines aim to prevent malaria caused by the Plasmodium falciparum parasite. Researchers will check how safe the vaccines are, how well …
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
New vaccines aim to block malaria transmission in africa
⭐️ VACCINE ⭐️ OngoingThis study tests two experimental vaccines designed to stop the malaria parasite from spreading from person to person. The vaccines target the parasite's development inside mosquitoes, so vaccinated people who get bitten are less likely to pass the infection on. The trial involve…
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
New malaria vaccine trial aims to protect women and their future babies
⭐️ VACCINE ⭐️ OngoingThis study tests the R21/Matrix-M1 malaria vaccine in 330 healthy women aged 18–35 in Mali who may become pregnant. Participants receive two or three doses of the vaccine or a placebo, and are followed for two years to check safety, immune response, and protection against malaria…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
Major malaria vaccine trial could save thousands of children
⭐️ VACCINE ⭐️ OngoingThis large-scale study tests the R21/Matrix-M vaccine to prevent malaria in 4,800 children aged 5-36 months living in Africa. The vaccine aims to protect against the most dangerous form of malaria. Researchers will measure how well it works and check for side effects over one yea…
Phase: PHASE3 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:07 UTC
-
Dengue vaccine gets a makeover: new formula tested in phase 3 trial
⭐️ VACCINE ⭐️ OngoingThis phase 3 trial is testing whether a new formulation of Takeda's dengue vaccine (TDV) works as well as the current approved version. About 496 healthy adults aged 18-60 who have never had dengue will receive two shots three months apart. The main goal is to compare immune resp…
Phase: PHASE3 • Sponsor: Takeda • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:05 UTC
-
Brazilian pilot program tests chikungunya Vaccine's Real-World power
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONThis study will track 1200 people in Brazil who received the VLA1553 chikungunya vaccine as part of a pilot program. Researchers will compare how many vaccinated and unvaccinated people get chikungunya to see if the vaccine works in everyday life. The goal is to understand the va…
Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
5,000 volunteers tracked to see if chikungunya vaccine is safe
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONThis observational study will follow 5,000 people who received the VLA1553 chikungunya vaccine as part of a pilot vaccination program. Researchers will monitor for specific safety concerns like chikungunya-like reactions, heart problems, and arthritis over 60 days. The goal is to…
Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
Chikungunya vaccine trial for kids pulled before start
⭐️ VACCINE ⭐️ TerminatedThis study was designed to test a vaccine called VLA1553 to protect healthy children aged 1 to 11 years from chikungunya, a virus spread by mosquitoes. The plan was to give the vaccine or a comparison shot to over 3,000 children and check for immune responses and safety. However,…
Phase: PHASE3 • Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:07 UTC
-
Chikungunya vaccine shows promise for Long-Term protection
⭐️ VACCINE ⭐️ OngoingThis Phase 3 trial follows adults who previously received the VLA1553 chikungunya vaccine to see how long their antibodies last and to monitor long-term safety. About 363 participants are being tracked for up to several years. The goal is to determine if a single shot can provide…
Phase: PHASE3 • Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC
-
Promising malaria vaccine trial launches for children in burkina faso
⭐️ VACCINE ⭐️ OngoingThis study tests a new malaria vaccine called SUM-101 in 69 healthy children and infants aged 5 months to 5 years in Burkina Faso. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive three doses, and some infants also receive a ra…
Phase: PHASE1 • Sponsor: European Vaccine Initiative • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:59 UTC
-
New vaccine against rift valley fever shows promise in early trial
⭐️ VACCINE ⭐️ OngoingThis Phase 2 trial tests a new vaccine called ChAdOx1 RVF against Rift Valley fever in 240 healthy adults in Kenya. Participants receive either one or two doses of the vaccine or a rabies vaccine as a control. Researchers will check if the vaccine triggers a strong immune respons…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:57 UTC
-
New vaccine aims to stop rare but deadly brain infections from mosquitoes
⭐️ VACCINE ⭐️ OngoingThis Phase 2 trial tests a new vaccine called MVA-BN-WEV to prevent two types of equine encephalitis (Eastern and Venezuelan), which are rare but serious brain infections spread by mosquitoes. The study involves 411 healthy adults aged 18-50 and aims to find the best dose and dos…
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC
-
New oral drug shows promise against deadly lassa fever in west africa trial
Disease control OngoingThis study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is t…
Phase: PHASE2 • Sponsor: Arisan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Dengue drug trial pulled before it even started
Disease control TerminatedThis study aimed to test a drug called IC14 in adults with early dengue fever to see if it is safe and could help reduce symptoms and viral levels. It was designed for people in areas where dengue is common, but the trial was withdrawn before any participants were enrolled. No re…
Phase: PHASE2 • Sponsor: Implicit Bioscience • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Hope for Hard-to-Treat lung infection: old drug shows promise
Disease control OngoingThis study tests a drug called clofazimine for people with a chronic lung infection caused by Mycobacterium avium complex (MAC). The goal is to see if adding clofazimine to standard treatment helps clear the bacteria from sputum and improves walking ability and fatigue. About 102…
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Scrub typhus showdown: which antibiotic works best when resistance is rising?
Disease control OngoingThis study tests three antibiotic regimens for scrub typhus, a bacterial infection spread by mites. Researchers compare 7 days of doxycycline, 3 days of doxycycline, and 3 days of azithromycin in 177 hospitalized patients aged 15 and older. The goal is to see which treatment clea…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Chagas drug shows promise for kids in landmark trial
Disease control OngoingThis study tests whether the drug benznidazole can cure chronic Chagas disease in children aged 2 to 18. All 178 participants receive the drug, and their results are compared to a historical placebo group. The main goal is to see if the infection clears based on blood tests over …
Phase: PHASE3 • Sponsor: Insud Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase: PHASE3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New bed nets take on mosquito resistance in malaria battle
Disease control OngoingThis trial compares two new types of insecticide-treated bed nets against standard nets to see if they better prevent malaria in children aged 6 months to 10 years in central Côte d'Ivoire. About 1,650 people are taking part across multiple villages. The new nets contain either a…
Phase: NA • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a simple nutrient supplement boost malaria protection in kids?
Disease control OngoingThis study tests whether adding a daily nutrient supplement (SQ-LNS) to monthly malaria prevention visits can reduce both malaria and malnutrition in children aged 6-24 months in Burkina Faso. Researchers will compare malaria rates and nutritional status between children receivin…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a rectal gel save children with severe malaria in remote villages?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether giving a rectal gel (rectal artesunate) followed by three days of malaria pills works as well as the standard injected treatment for young children with severe malaria. It involves about 2,000 children aged 6 months to 5 years in remote areas of Zambia…
Sponsor: Tropical Diseases Research Centre, Zambia • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can an arthritis drug tame deadly dengue inflammation?
Disease control OngoingThis study tests whether anakinra, an anti-inflammatory drug, can help people with severe dengue who have dangerously high inflammation. About 160 adults and children will receive either anakinra or a placebo for four days. The goal is to see if anakinra reduces organ failure and…
Phase: PHASE2 • Sponsor: Oxford University Clinical Research Unit, Vietnam • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Twice-Yearly drug could beat river blindness
Disease control OngoingThis study tests if taking moxidectin twice a year is safer and more effective than once a year for treating river blindness, a parasitic disease. About 323 people in the Democratic Republic of Congo will receive either moxidectin or ivermectin annually or biannually. The goal is…
Phase: PHASE3 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktails aim to beat river blindness
Disease control OngoingThis study tests four different drug combinations in 300 adults with onchocerciasis (river blindness), a parasitic disease. Participants first receive ivermectin to clear skin and eye parasites, then get one of the new combos. The goal is to see which combo is safest and most eff…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New malaria drug combo shows promise in kids
Disease control OngoingThis study looked at how two different malaria drug combinations work in children with uncomplicated malaria in Zambia. The goal was to see how well the drugs clear malaria parasites from the blood and prevent new infections for up to 9 weeks. About 182 children took part, and re…
Phase: PHASE2, PHASE3 • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a common arthritis drug tame chikungunya joint pain?
Disease control OngoingThis phase 3 trial tests whether methotrexate, a drug used for rheumatoid arthritis, can reduce joint swelling and pain in people with chronic arthritis caused by chikungunya virus. About 150 adults in Colombia will receive either methotrexate or a placebo for 6 months. The goal …
Phase: PHASE3 • Sponsor: George Washington University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could your own skin heal a diabetic foot ulcer? new program tests SkinTE
Disease control TEMPORARILY_NOT_AVAILABLEThis expanded access program offers SkinTE, a treatment made from a small piece of the patient's own healthy skin, to people with Wagner 1 diabetic foot ulcers. The goal is to see if applying these skin cells directly to the wound can help it heal. The program also collects safet…
Sponsor: PolarityTE • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Papaya leaf extract tested as dengue treatment for kids
Disease control ENROLLING_BY_INVITATIONThis study tests whether papaya leaf extract syrup can raise low platelet counts in children aged 2–12 with dengue fever. One hundred children will receive either standard care alone or standard care plus the extract for three days. Researchers will compare platelet changes and w…
Phase: PHASE2 • Sponsor: Ziauddin Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:24 UTC
-
New wound scanner aims to spot hidden bacteria
Diagnosis ENROLLING_BY_INVITATIONThis study compares a new device, cureVision cV, to an existing one (MolecuLight i:X) to see if it can accurately detect moderate to high levels of bacteria in wounds. About 100 adults with various wound types (like diabetic foot ulcers or surgical wounds) will be enrolled. The g…
Phase: NA • Sponsor: Capsicure, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New rapid test could speed up tropical fever diagnosis
Diagnosis ENROLLING_BY_INVITATIONThis study evaluates a new blood test called Xpert Tropical Fever that can quickly detect several tropical diseases like malaria, dengue, and Zika from a small blood sample. Researchers will enroll 2,500 people with fever symptoms to see how accurate the test is compared to stand…
Sponsor: Cepheid • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
Malaria vaccine trial for pregnant women launches in mali
Prevention TerminatedThis Phase 1 trial in Mali will test the safety of the PfSPZ malaria vaccine in 400 healthy pregnant women aged 18-34. Participants will receive three injections of either the vaccine or a placebo. The study will monitor both mothers and their infants for up to a year after birth…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
Malaria prevention in infants may strengthen immunity for years
Prevention OngoingThis Phase 3 trial in Uganda tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks to 1 or 2 years of age helps them develop stronger immunity against malaria later. 924 children are enrolled and followed until age 4…
Phase: PHASE3 • Sponsor: Grant Dorsey, M.D, Ph.D. • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
New shot aims to stop the plague before it starts
Prevention OngoingThis early-stage study tests whether a single injection of a new antibody, JST-010, is safe in healthy adults aged 18 to 55. The goal is to prevent pneumonic plague, a rare but serious lung infection. Researchers compare the antibody to a placebo and monitor participants for one …
Phase: PHASE1 • Sponsor: Just-Evotec Biologics • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
Simple malaria test in early pregnancy could save newborns
Prevention OngoingThis study tests whether screening pregnant women for malaria with a highly sensitive rapid test during the first trimester, followed by treatment if positive, can improve newborn health. Over 2,000 women in malaria-prone areas will be compared to those receiving usual care. The …
Phase: PHASE4 • Sponsor: Duke University • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
Malaria prevention study pulled before it began
Prevention TerminatedThis study aimed to see if sending health workers to find malaria cases in high-risk villages and among forest workers could lower malaria rates better than usual care. It planned to track infections over 18 months in southern Laos. However, the study was withdrawn before any par…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
Could a simple antibiotic added to childhood vaccines save thousands of young lives?
Prevention OngoingThis large study in Sierra Leone is testing whether giving children an antibiotic (azithromycin) along with malaria prevention medicine during their regular vaccine visits can lower the number of deaths in children under 5. Over 20,000 children are taking part. The goal is to fin…
Phase: PHASE3 • Sponsor: Barcelona Institute for Global Health • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo IDB-011 tested for safety against rift valley fever
Prevention OngoingThis early-stage trial is testing the safety of a new drug combination called IDB-011 in 40 healthy adults. The goal is to see if it is safe and how the body processes it, as a first step toward possibly preventing Rift Valley Fever, a viral disease spread by mosquitoes. Particip…
Phase: PHASE1 • Sponsor: IDBiologics, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Mass malaria drug campaign aims to stop parasite spread in senegal
Prevention OngoingThis study tests whether giving antimalarial drugs to entire communities can reduce malaria transmission. About 18,000 people in 50 villages in Senegal will take part. The goal is to clear hidden malaria parasites that standard treatments miss, especially during the dry season.
Phase: NA • Sponsor: Institut de Recherche pour le Developpement • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
School-Based malaria prevention could shield entire villages
Prevention OngoingThis study tests whether giving school children preventive malaria medicine can reduce infections not only in them but also in younger siblings at home. About 1,000 students in rural Malawi will receive either one of two drug combinations or no preventive treatment. Researchers w…
Phase: PHASE4 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
New malaria prevention combo tested in mali infants
Prevention OngoingThis study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 07:52 UTC
-
Umbilical cord particles show promise for stubborn wounds
Symptom relief ENROLLING_BY_INVITATIONThis small study is testing Corplex P, a device made from donated human umbilical cord tissue, to see if it helps heal wounds that won't close on their own, like diabetic foot ulcers. Ten people will receive the device as part of their standard wound care. Researchers will track …
Sponsor: StimLabs • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can a nerve zap in the ear ease chikungunya joint pain?
Symptom relief OngoingThis study tests a gentle electrical stimulation of the vagus nerve in the ear (taVNS) to reduce chronic joint pain in the legs caused by Chikungunya fever. 51 adults with pain lasting at least 3 months will be randomly assigned to taVNS, standard TENS, or a sham device. The goal…
Phase: NA • Sponsor: Universidade Federal de Pernambuco • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Mystery infections in healthy people: scientists investigate
Knowledge-focused OngoingThis study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Laser light may reveal secrets of skin elasticity
Knowledge-focused OngoingThis study explores how low-level laser therapy (LLLT) affects skin stiffness and thickness. Researchers will use a special imaging system to track tiny skin movements in 20 healthy adults. The goal is to find the best laser settings for future wound healing treatments.
Phase: NA • Sponsor: Asia University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and e…
Phase: NA • Sponsor: Peking University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Malaysia monitors QDENGA vaccine safety in 2,000 people
Knowledge-focused OngoingThis study tracks side effects and severe dengue cases in 2,000 people who already got the QDENGA dengue vaccine in Malaysia. No new vaccine is given—researchers simply collect health data from participants. The goal is to understand real-world safety and whether vaccinated peopl…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Breastfeeding moms with malaria: do drugs reach baby?
Knowledge-focused OngoingThis study tracks how the malaria drug artemether-lumefantrine passes from a breastfeeding mother into her breastmilk and then into her nursing infant. Researchers will take blood and milk samples from 30 mother-infant pairs in Uganda over two weeks. The goal is to understand dru…
Sponsor: University of Liverpool • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can tracking where people go stop dengue? new study says yes
Knowledge-focused OngoingThis study aims to improve how we predict and prevent dengue outbreaks by looking at how people move around the city. Researchers in Cuba will collect information from 810 residents about their daily travel, along with mosquito and weather data. The goal is to build better comput…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Massive dengue vaccine rollout under the microscope: 800,000 recipients analyzed
Knowledge-focused OngoingThis study reviews the records of up to 800,000 people who received the TAK-003 (Qdenga) dengue vaccine at VNVC centers in Vietnam between September 2024 and September 2025. Researchers will look at age, sex, location, and vaccination history to see who got the vaccine and how. N…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Malaria vaccine study pulled before it began
Knowledge-focused TerminatedThis study was designed to see if giving a single dose of an antibody called L9LS changes how well the R21/Matrix-M malaria vaccine works. It planned to enroll healthy adults and infants in Mali. However, the trial was withdrawn before any participants were enrolled, so no data w…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
AI predicts hospital stays, but study never started
Knowledge-focused TerminatedThis study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Brazil Pre-Vaccination survey gauges chikungunya immunity
Knowledge-focused OngoingThis study will test over 5,300 people in about 10 Brazilian municipalities for antibodies to the chikungunya virus before a pilot vaccination campaign with the VLA1553 vaccine. The goal is to see how many people have already been exposed to the virus and how that might affect va…
Sponsor: Valneva Austria GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Liberia malaria study aims to guide future vaccine use
Knowledge-focused OngoingThis study tracks how often people of all ages in two Liberian villages get malaria, and how many mosquitoes carry the parasite. Researchers will test blood samples monthly and collect mosquitoes from homes. The goal is to gather data that could help decide the best way to use a …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Dengue vaccine strategy study aims to protect yunnan communities
Knowledge-focused OngoingThis study, run by Fudan University and local health authorities, uses computer models to predict the best way to use dengue vaccines in Yunnan, China. Researchers will collect blood samples from 220 residents to measure antibody levels and simulate different vaccination scenario…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Simple test may uncover hidden tick-borne brain infections
Knowledge-focused ENROLLING_BY_INVITATIONThis study reviews medical records of 200 people hospitalized with unexplained meningitis or meningoencephalitis. Researchers want to see if adding a test for tick-borne encephalitis (TBE) helps find more cases. No new drug or treatment is being tested—only the impact of a change…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Dengue vaccine study aims to unlock immune secrets
Knowledge-focused OngoingThis study looks at how the Takeda dengue vaccine (TAK-003) activates T-cells, a key part of the immune system. Researchers will vaccinate 30 healthy adults and analyze their T-cell and antibody responses over 26 weeks. The goal is to find reliable markers of protection, which co…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:29 UTC